Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Valery Z Grdzelishvili"'
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104688 (2014)
Virus particles (virions) often contain not only virus-encoded but also host-encoded proteins. Some of these host proteins are enclosed within the virion structure, while others, in the case of enveloped viruses, are embedded in the host-derived memb
Externí odkaz:
https://doaj.org/article/83425b82c3b9488aa5f2cd8c0f44879b
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e11265 (2010)
Ribavirin (RBV) is a synthetic nucleoside analog with broad spectrum antiviral activity. Although RBV is approved for the treatment of hepatitis C virus, respiratory syncytial virus, and Lassa fever virus infections, its mechanism of action and thera
Externí odkaz:
https://doaj.org/article/dde7dde088a34c418106bc3e0f09cc5b
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 24, Iss, Pp 59-76 (2022)
Molecular Therapy: Oncolytics, Vol 24, Iss, Pp 59-76 (2022)
Vesicular stomatitis virus (VSV) is a promising oncolytic virus (OV) against different malignancies, including pancreatic ductal adenocarcinoma (PDAC). Our previous studies have demonstrated that VSV-based OVs are effective against the majority of te
Publikováno v:
Cancers, Vol 13, Iss 1171, p 1171 (2021)
Cancers
Cancers
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a poor prognosis and a dismal survival rate. Oncolytic virus (OV) is an anticancer approach that utilizes replication-competent viruses to preferentially infect a
Publikováno v:
Journal of Virology
Vesicular stomatitis virus (VSV)-based oncolytic viruses are promising agents against pancreatic ductal adenocarcinoma (PDAC). However, some PDAC cell lines are resistant to VSV. Here, using a directed viral evolution approach, we generated novel onc
Publikováno v:
Journal of General Virology. 98:2895-2911
Oncolytic virus (OV) therapy is an anti-cancer approach that uses viruses that preferentially infect, replicate in and kill cancer cells. Vesicular stomatitis virus (VSV, a rhabdovirus) is an OV that is currently being tested in the USA in several ph
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 20-40 (2017)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant cells unharmed. With the first U.S. Food and Drug Administration-approved OV, dozens of clinical trials ongoing, and an abundance of trans
Autor:
Christian Bressy, Bryant D. Maldonado, Gaith N. Droby, Nury Steuerwald, Valery Z. Grdzelishvili
Publikováno v:
Journal of Virology. 93
Vesicular stomatitis virus (VSV) (a rhabdovirus) and its variant VSV-ΔM51 are widely used model systems to study mechanisms of virus-host interactions. Here, we investigated how the cell cycle affects replication of these viruses using an array of c
Autor:
Nury Steuerwald, Valery Z. Grdzelishvili, Eric Hastie, Megan Moerdyk-Schauwecker, Sébastien A. Felt, Marcela Cataldi
Publikováno v:
Oncotarget
// Eric Hastie 1, * , Marcela Cataldi 1, * , Megan J. Moerdyk-Schauwecker 1, * , Sebastien A. Felt 1, * , Nury Steuerwald 2 , Valery Z. Grdzelishvili 1 1 Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA
Autor:
Christian, Bressy, Gaith N, Droby, Bryant D, Maldonado, Nury, Steuerwald, Valery Z, Grdzelishvili
Publikováno v:
Journal of Virology
Vesicular stomatitis virus (VSV) (a rhabdovirus) and its variant VSV-ΔM51 are widely used model systems to study mechanisms of virus-host interactions. Here, we investigated how the cell cycle affects replication of VSV and VSV-ΔM51. We show that G